Prognostic Influence of Loss of Blood Group A Antigen Expression in Pathologic Stage I Non-Small-Cell Lung Cancer

详细信息    查看全文

• 作者：Pablo Leó ; n-Atance^a ; ^{pabl1150@separ.es} ; Nicol&#225 ; s Moreno-Mata^b ; Federico Gonz&#225 ; lez-Aragoneses^c ; Miguel Á ; ngel Cañ ; izares-Carretero^d ; Enrique Poblet-Martí ; nez^e ; Marta Genové ; s-Crespo^a ; Marí ; a Dolores Garcí ; a-Jimé ; nez^a ; Antonio Francisco Honguero-Martí ; nez^a ; Carlos Alberto Rombol&#225 ; ^a ; Carlos Marí ; a Simó ; n-Adiego^c ; Rafael Peñ ; alver-Pacual^c ; Emilio Á ; lvarez-Fern&#225 ; ndez^f
• 关键词：Blood group antigen A (BAA) ; Lung adenocarcinoma ; Non-small-cell lung cancer (NSCLC) ; Pathologic stage ; Prognostic factors
• 刊名：Archivos de Bronconeumología (English Edition)
• 出版年：2012
• 出版时间：February 2012
• 年：2012
• 卷：48
• 期：2
• 页码：49-54
• 全文大小：612 K

文摘

Introduction

In the scientific literature, contradictory results have been published on the prognostic value of the loss of expression of blood group antigen A (BAA) in lung cancer. The objective of our study was to analyze this fact in our surgical series.

Patients and methods

In a multicenter study, 402 non-small-cell lung cancer (NSCLC) patients were included. All were classified as stage-I according to the last 2009-TNM classification. We analyzed the prognostic influence of the loss of expression of BAA in the 209 patients expressing blood group A or AB.

Results

The 5-year cumulative survival was 73 % for patients expressing BAA vs 53 % for patients with loss of expression (P=.03). When patients were grouped into stages IA and IB, statistical significance was only observed in stage I-A (P=.038). When we analyzed the survival according to histologic type, those patients with adenocarcinoma and loss of expression of BAA had a lower survival rate that was statistically very significant (P=.003). The multivariate analysis showed that age, gender and expression of BAA were independent prognostic factors.

Conclusions

The loss of expression of blood group antigen A has a negative prognostic impact in stage I NSCLC, especially in patients with adenocarcinoma.